(Q40383481)

20 September 2017

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma (English)

1 reference

20 September 2017

1 reference

Chodak G

1

1 reference

20 September 2017

Sharifi R

2

1 reference

20 September 2017

Kasimis B

3

1 reference

20 September 2017

Block NL

4

1 reference

20 September 2017

Macramalla E

5

1 reference

20 September 2017

Kennealey GT

6

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 December 1995

1 reference

20 September 2017

1 reference

20 September 2017

46

1 reference

20 September 2017

6

1 reference

20 September 2017

849-855

1 reference

STUDIES ON PROSTATIC CANCER

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

Clinical profile of a new non-steroidal antiandrogen.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urolo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

Flutamide as primary treatment for metastatic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

Current clinical studies with a new nonsteroidal antiandrogen, Casodex

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980356-2

7 January 2021

10.1016/S0090-4295(99)80356-2

Identifiers

DOI

1 reference

20 September 2017

1 reference